Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$21.74 -2.5%	$17.87	$13.40 ▼ $25.23	$3.64B	0.65	1.94 million shs	1.56 million shs
FIXX Homology Medicines		$1.18	$0.46 ▼ $17.51	$978.01M	-0.1	390,307 shs	22,300 shs
MRUS Merus	$55.39 +0.6%	$46.03	$33.19 ▼ $62.98	$3.83B	1.04	750,640 shs	1.50 million shs
MTSR Metsera	$34.58 +4.6%	$23.72	$12.30 ▼ $37.99	$3.63B	N/A	910,908 shs	482,327 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.45%	+2.43%	+27.28%	+32.90%	+48.37%
FIXX Homology Medicines	0.00%	0.00%	0.00%	0.00%	0.00%
MRUS Merus	-2.48%	-4.39%	+29.80%	+15.55%	-3.61%
MTSR Metsera	-5.81%	+15.68%	+25.32%	+36.27%	+3,305,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.242 of 5 stars	3.3	1.0	0.0	0.0	3.3	4.2	1.3
FIXX Homology Medicines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRUS Merus	3.2445 of 5 stars	4.6	3.0	0.0	0.0	2.6	1.7	0.0
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.69	Moderate Buy	$26.79	23.21% Upside
FIXX Homology Medicines	0.00	N/A	N/A	N/A
MRUS Merus	3.13	Buy	$85.83	54.96% Upside
MTSR Metsera	3.00	Buy	$50.00	44.59% Upside

Current Analyst Ratings Breakdown

Latest FIXX, MRUS, MTSR, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	MTSR Metsera	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $62.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $31.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$26.00 ➝ $26.00
5/19/2025	ACAD ACADIA Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$24.00 ➝ $28.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$996.28M	3.65	N/A	N/A	$2.63 per share	8.27
FIXX Homology Medicines	$1.16M	0.00	N/A	N/A	$1.26 per share	0.00
MRUS Merus	$54.73M	70.05	N/A	N/A	$6.17 per share	8.98
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.37	27.87	28.61	N/A	13.83%	25.83%	14.71%	8/5/2025 (Estimated)
FIXX Homology Medicines	-$112.96M	-$1.96	N/A	N/A	N/A	-4,779.31%	-102.52%	-74.91%	N/A
MRUS Merus	-$154.94M	-$4.08	N/A	N/A	N/A	-680.61%	-38.89%	-31.16%	7/30/2025 (Estimated)
MTSR Metsera	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest FIXX, MRUS, MTSR, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/12/2025	Q1 2025	MTSR Metsera	N/A	-$1.03	N/A	-$1.03	N/A	N/A
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
3/26/2025	N/A	MTSR Metsera	N/A	-$3.52	N/A	-$3.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FIXX Homology Medicines	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
FIXX Homology Medicines	N/A	7.25	7.25
MRUS Merus	N/A	8.32	8.32
MTSR Metsera	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
FIXX Homology Medicines	31.32%
MRUS Merus	96.14%
MTSR Metsera	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
FIXX Homology Medicines	16.10%
MRUS Merus	4.57%
MTSR Metsera	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	119.30 million	Optionable
FIXX Homology Medicines	7	58.13 million	48.77 million	Optionable
MRUS Merus	37	69.21 million	65.34 million	Optionable
MTSR Metsera	81	105.06 million	N/A	N/A

FIXX, MRUS, MTSR, and ACAD Headlines

Recent News About These Companies

Metsera (NASDAQ:MTSR) Shares Up 4.5% - Time to Buy?

June 12 at 4:58 PM | marketbeat.com

Promising Results Of Amylin Analogs In Obesity: Metsera Case Review

June 12 at 10:03 AM | seekingalpha.com

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results

June 11 at 11:59 PM | msn.com

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med

June 11 at 6:59 PM | medcitynews.com

Cantor Fitzgerald Estimates Metsera FY2026 Earnings

June 11 at 9:03 AM | marketbeat.com

Metsera (NASDAQ:MTSR) Shares Gap Up Following Analyst Upgrade

June 11 at 1:07 AM | americanbankingnews.com

Metsera extends gains after early-stage trial data for obesity therapy

June 10 at 6:42 PM | msn.com

Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating

June 10 at 1:41 PM | msn.com

Metsera (NASDAQ:MTSR) Shares Gap Up After Analyst Upgrade

June 10 at 11:35 AM | marketbeat.com

Guggenheim Issues Positive Forecast for Metsera (NASDAQ:MTSR) Stock Price

June 10 at 11:10 AM | marketbeat.com

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 10 at 7:00 AM | globenewswire.com

Metsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

June 9 at 5:16 PM | finanznachrichten.de

Metsera shares soar on positive amylin candidate trial results

June 9 at 5:16 PM | investing.com

Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch

June 9 at 5:16 PM | msn.com

Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes

June 9 at 5:16 PM | msn.com

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

June 9 at 2:34 PM | benzinga.com

Metsera (NASDAQ:MTSR) Hits New 12-Month High - What's Next?

June 9 at 12:18 PM | marketbeat.com

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

June 9 at 12:04 PM | reuters.com

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

June 9 at 7:00 AM | globenewswire.com

Metsera (NASDAQ:MTSR) Shares Down 3.7% - Should You Sell?

June 8, 2025 | americanbankingnews.com

Metsera (NASDAQ:MTSR) Trading Down 3.7% - Here's Why

June 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FIXX, MRUS, MTSR, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.74 -0.56 (-2.51%)

As of 04:00 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Homology Medicines NASDAQ:FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Merus NASDAQ:MRUS

$55.39 +0.34 (+0.62%)

As of 04:00 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Metsera NASDAQ:MTSR

$34.58 +1.52 (+4.60%)

As of 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time